InvestorsHub Logo
Followers 7
Posts 789
Boards Moderated 0
Alias Born 11/20/2003

Re: Waxman post# 11811

Monday, 07/24/2017 10:22:45 PM

Monday, July 24, 2017 10:22:45 PM

Post# of 12450
This stock is thinly traded and does not gave enough depth .Any small selloff can hurt tge price of the stock.The company announced that of 7.0 plus in warrants at $.56 .2 4 n shares were exercised as of 7/17 and that Over 4 M
Have not been exercised at $.56 That would bring in $2.4 M cash to the companies balance sheet.So there were about 64 M shares currently outstanding
These people probably exercised the warrants and locked in their gains at the highs.

Seems to me that the added dilution
Also brings extra cash that maybe overlooked as

We need some catalysts like s partner
For cislis,news on the patent front

I think the licensing and marketing for tadafil will be quite substantial and their biggest payment yet not including their manufacturing gross profit of over 40 percent.

For example $5_ $10 M licensing fee
and 40 percent gross profit on $300-$400M with s net of 8 to 10 percent
$30-$40 M divided my 75 M shares
$.60 net profit times a p/e of 8 equals
$4.80. I think this will materialize at this level in 2019 but will start to ramp up in late 2018. this is all a guess though
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News